Angelalign Technology (HKG:6699) First Half 2024 Results
Key Financial Results
- Revenue: CN¥861.5m (up 40% from 1H 2023).
- Net income: CN¥22.5m (down 30% from 1H 2023).
- Profit margin: 2.6% (down from 5.2% in 1H 2023).
- EPS: CN¥0.13 (down from CN¥0.19 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Angelalign Technology Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 51%.
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are up 12% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Angelalign Technology has 2 warning signs we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.